ImmunoVaccine Technologies’ DepoVax(TM) Shows Positive Results For Cancer And Infectious Diseases

ImmunoVaccine Technologies’ (IVT) patented depot vaccine formulation, DepoVax(TM) is showing positive pre-clinical results, with single-dose efficacy achieved in therapeutic cancer and several infectious disease vaccine models. The results of this research will be presented October 4th at the Ehrlich II conference in Germany. Collaborators from the University of Miami will also be reporting on the capabilities of IVT’s depot formulations for delivery of DNA and SiRNA in vivo.

DepoVax(TM) provides a unique single-dose capability, and is based on a novel approach to the use of liposomes, which encapsulate a target antigen and adjuvant. The vaccine formulation also relies on a hydrophobic oil carrier. The result is a depot effect that significantly enhances vaccine induced cell-mediated and humoral immunity.

The efficacy of a single dose of a DepoVax(TM) formulation was shown using a Human Papilloma Virus (HPV) associated cervical cancer model. In the therapeutic C3 tumor challenge model, DepoVax(TM) eliminated 100% of established cancerous tumors after a single dose. In contrast, tumors remained intact when treated with a placebo vaccine. The effect of the vaccine is linked to the activation of a potent and specific cellular immune response.

Read more ….

MedicalNewsToday.com